Authors
Michael A Serwetnyk, Parthasaradhireddy Tanguturi, Terin D'Amico, Yoshihiro Morishima, Miranda Lau, Ian Mersich, Deborah Barlow, Karen L Houseknecht, Yoichi Osawa, John M Streicher, Aktar Ali, Brian S J Blagg
Published in
Journal of medicinal chemistry. Volume 69. Issue 21. Pages 26354-26374. Nov 12, 2026.
Abstract
The clinical evaluation of 90 kD heat shock protein (Hsp90) inhibitors has been hindered by their detrimental, pan-inhibitory activities. Consequently, the development of Hsp90 isoform-selective inhibitors has been pursued. Although prior compounds have elucidated the roles of Hsp90β in cancer immunotherapy and opioid therapy, their sub-optimal drug-like properties have required extensive optimization campaigns to enhance this scaffold's pharmacological profile. The work presented herein expands upon previous efforts by introducing simultaneous modifications to the "northern" indazolone fragment and "southwestern" appendage to determine whether combinations of the properties at these regions can produce improved Hsp90β-selective inhibitors. These chimeric inhibitors reveal that such modifications can retain Hsp90β affinity/selectivity, while modulating key pharmacokinetic parameters and anticancer activity. Notably, one derivative (8b) also exhibits oral bioavailability and enhances opioid antinociception in a murine model for chronic pain. These findings support the continued development of Hsp90β-selective inhibitors for anticancer therapy, chronic pain management, and other disease indications.
PMID:
43018549
Bibliographic data and abstract were imported from PubMed on 12 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 5
- Comments 0